Seyed Mohammad Nabavi, Kasi Pandima Devi, Sethuraman Sathya, Ana Sanches-Silva*, Listos Joanna, Sylwia Talarek, Suowen Xu, Maria Daglia, Seyed Fazel Nabavi, Samira Shirooie, Antoni Sureda*, Silvia Tejada, Maciej Banach, Ahmad Reza Dehpour and Luciano Saso Pages 4004 - 4022 ( 19 )
Obesity is a major health concern for a growing fraction of the population, as its prevalence and related metabolic disorders are not fully understood. Over the last decade, many attempts have been undertaken to understand the mechanisms at the basis of this condition, in which the accumulation of fat occurring in adipose tissue leads to the pathogenesis of obesity- related disorders. Among the most recent studies, those on Peroxisome Proliferator Activated Receptors (PPARs) revealed that these nuclear receptor proteins acting as transcription factors, among others, regulate the expression of genes involved in energy, lipid, and glucose metabolisms, and chronic inflammation. The three different isotypes of PPARs, with different tissue expression and ligand binding specificity, exert similar or overlapping functions directly or indirectly linked to obesity. In this study, we reviewed the available scientific reports concerning the PPARs structure and functions, especially in obesity, considering both natural and synthetic ligands and their role in the therapy of obesity and obesity-associated disorders. On the whole, the collected data suggest that there are both natural and synthetic compounds that show beneficial and promising activity as PPAR agonists in chronic diseases related to obesity.
Obesity, Cardiovascular, Peroxisome proliferator–activated receptors, Endogenous and exogenous ligands, Natural and synthetic agonists, PPAR, natural remedy for obesity.
Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Department of Biotechnology, Alagappa University, Karaikudi-630003, Tamil Nadu, Department of Biotechnology, Alagappa University, Karaikudi-630003, Tamil Nadu, National Institute for Agricultural and Veterinary Research (INIAV), I.P., Rua dos Lagidos, Lugar da Madalena, 4485-655, Vairao, Vila do Conde, Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, Chodzki 4a St., 20-093 Lublin, Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, Chodzki 4a St., 20-093 Lublin, Aab Cardiovascular Research Institute, University of Rochester, Rochester, NY, 14623, Department of Pharmacy, University of Napoli Federico II, Via D. Montesano 49, 80131, Naples, Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Pharmaceutical Sciences Research Center, Kermanshah University of Medical Sciences, Kermanshah, CIBEROBN (Physiopathology of Obesity and Nutrition), E-07122, Palma de Mallorca, Balearic Islands, CIBEROBN (Physiopathology of Obesity and Nutrition), E-07122, Palma de Mallorca, Balearic Islands, Department of Hypertension, Medical University of Lodz, Lodz, Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Department of Physiology and Pharmacology “Vittorio Erspamer”, Sapienza University of Rome, P. le Aldo Moro 5, 00185 Rome